GPR171 As a Novel Target to Treat Neuropathic Pain
GPR171 As a Novel Target to Treat Neuropathic Pain
批准号:
10217478
负责人:
Erin Nicole Bobeck
金额:
$14.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-05-01 至 2024-04-30
关键词:
AgonistAmericanAreaBrainBrain regionCerebrospinal FluidChronicDataDevelopmentDisinhibitionEpidemicG-Protein-Coupled ReceptorsHealthHumanInjectionsKnowledgeLigandsMeasuresMediatingMolecularMorphineMusNeuronsNeuropeptidesOpioidOpioid AnalgesicsOrphanOutputPainPain managementPatientsPeptide ReceptorPeptidesPhysiologicalPropertyResearchRoleSignal TransductionSpinal CordSpinal cord posterior hornStimulusSystemTechniquesTestingTherapeuticTimeViralWorkallodyniabehavioral outcomebehavioral pharmacologychemotherapychemotherapy induced neuropathychronic neuropathic painchronic painchronic pain patienteffectiveness evaluationfibromyalgia patientsinnovationinterdisciplinary approachknock-downmidbrain central gray substancemu opioid receptorsneural circuitnovelopioid epidemicopioid useosmotic minipumppain behaviorpain modelpain patientpain reductionpain signalpainful neuropathyreceptorreceptor downregulationreceptor functionresponsetherapeutic target
中文摘要
项目摘要
数百万慢性疼痛患者缺乏足够的治疗方法来治疗他们的疼痛。孤儿g蛋白
偶联受体可能是一种新的途径,以研究治疗疼痛和各种
其他健康问题。一个有趣的候选者是GPR 171,最近被发现是
受体的高度丰富的神经肽,比格伦。这项研究的目的是
是研究这个系统的神经回路,BigLEN-GPR 171,以及它减轻
慢性疼痛我们的初步数据显示GPR 171激动剂具有抗伤害感受特性,
慢性疼痛此外,神经病理性疼痛下调GPR 171的表达在一个关键的时间点内,
大脑区域,导水管周围灰质,参与疼痛调节。我们的假设是
导水管周围灰质内的GPR 171调节神经性疼痛。为了验证这个假设,我们
将使用分子和行为药理学研究GPR 171激动剂,
化学疗法引起的神经性疼痛,并破译哪些大脑区域介导这些
应答目的1将确定用GPR 171激动剂长期治疗的有效性
治疗慢性神经性疼痛GPR 171表达和信号转导在细胞内的改变
慢性疼痛后的下行疼痛回路将在目标2a中使用分子生物学方法进行研究。
技术.目标2b将使用病毒敲除和GPR 171化合物的局部施用,
确定导水管周围灰质在缓解神经病理性疼痛中的作用。总体而言,这
创新研究具有重要的疼痛治疗意义,因为它将提高我们的
了解这种新的神经肽系统的生理功能。
英文摘要
PROJECT SUMMARY
Millions of chronic pain patients lack adequate therapeutics to treat their pain. Orphan G-protein
coupled receptors could be a new avenue to investigate for the treatment of pain and a variety
of other health concerns. One interesting candidate is GPR171 that recently was found to be the
receptor of the highly abundant neuropeptide, BigLEN. The purpose of this proposed research
is to investigate the neural circuitry of this system, BigLEN-GPR171, and its ability to alleviate
chronic pain. Our preliminary data show that a GPR171 agonist has antinociceptive properties
in chronic pain. In addition, neuropathic pain downregulates GPR171 expression within a key
brain region, periaqueductal gray, that is involved in pain modulation. Our hypothesis is that
GPR171 within the periaqueductal gray regulates neuropathic pain. To test this hypothesis, we
will use molecular and behavioral pharmacology to investigate a GPR171 agonist on
chemotherapy-induced neuropathic pain and decipher which brain areas are mediating these
responses. Aim 1 will determine the effectiveness of long-term treatment with a GPR171 agonist
on treating chronic neuropathic pain. Alterations in GPR171 expression and signaling within the
descending pain circuit following chronic pain will be investigated in Aim 2a by using molecular
techniques. Aim 2b will use viral knockdown and local administration of GPR171 compounds to
determine the role of the periaqueductal gray in relieving neuropathic pain. Overall, this
innovative research has important pain therapeutic implications, as it will enhance our
understanding of the physiological functions of this novel neuropeptide system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of the endogenous opioid neural circuitry in pain
-
批准号:10646973
-
项目类别:
-
资助金额:$7.3万
-
财政年份:2023
-
负责人:Erin Nicole Bobeck
-
依托单位:
海外基金